MACH7 TECHNOLOGIES LIMITED — Investor Presentation 2015

Jun 28, 2015

==> picture [720 x 131] intentionally omitted <==

3D Medical Limited Company Overview Dr. Nigel Finch, Chairman

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

DISCLAIMER
----- End of picture text -----

• Summary of information: This presentation contains general and background information about 3D Medical Limited (“ 3DM ”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by 3DM and all other documents provided to you by 3DM. 3DM is not responsible for providing updated information and assumes no responsibility to do so.

• Not financial product advice: This presentation is not a financial product, investment advice or a recommendation to acquire 3DM securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. 3DM is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of 3DM securities. 3DM assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

• Disclaimer: 3DM and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of 3DM.

• Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of 3DM. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

• Risks: An investment in 3DM securities is subject to investment and other known and unknown risks, some of which are beyond the control of 3DM. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

• Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in 3DM or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in 3DM will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of 3DM.

• No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by 3DM have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

• Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice.

• Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

• No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

• Confidential: This document contains information that is strictly confidential. By attending this presentation, you agree not to directly or indirectly disclose to any person or copy, use, publish or record in any form any part of this document.

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

3D MEDICAL LIMITED (ASX: 3DM)
----- End of picture text -----

3DM’s objective is to be the preferred partner for managing and utilising 3D imagery and data in the clinical setting

 RTO of Safety Medical Products (ASX:SFP) completed Feb 2015  Raised $4.1 million under prospectus @ $0.05 per share  Shares on issue: 375 million  Market capitalisation: ~$40 million  Cash positon: $3.5 million at March 2015

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

3D TECHNOLOGY AND HEALTHCARE
----- End of picture text -----

• Digital healthcare is now a reality

• Personalised data is increasingly being captured in high quality digital data sets through the use of CT and MRI machines, 3D Ultrasound and intraoral laser scanning

• Australian clinicians refer an estimated 10 million 3D volumetric images in Australia annually

• Australian medical providers are known to be early adopters of new medical technology & techniques

• The opportunity exists to pave the way for the use of 3D technologies in the Australian medical industry with the potential to improve diagnosis, patient care and treatment

• The benefits derived from adopting 3D technologies include:

• Positive patient outcomes by enabling pre-surgery planning and preparation

• Economic benefits by reducing the time and cost of surgery

• Enhanced teaching techniques with pathway to excellence in surgical training

• The Australasian medical market opportunity for advanced 3D technologies is significant and growing, driven by an increasing demand for both personalised medical solutions and diagnostic imaging services

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

PROCESS
----- End of picture text -----

Capture conventional DICOM data

2D cross sections

Image processing software

Anatomically correct 3D virtual reality model

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

HEATHCARE SEGMENTATION
----- End of picture text -----

 Volume rendering for diagnostic teams

 3D geometry for clinical teams

Volume rendering

Surface rendering

3D PRINTING MARKET APPLICATIONS

Pre-Clinical

• •Plan and practice early interventions

• •Efficient physician communication

• •Reduces cost

Training/Education

• •Understand the pathology •Superior training

• •Efficient communication

Custom Implants •Patient specific •Faster procedures •Decreased possibility of infection •Better patient outcomes

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

INITIAL PRODUCT SUITE
----- End of picture text -----

Product Description Revenue

3D printed models 1. and implants

• Sale of 3D printed models to surgeons for preoperative planning and education, patient communication, medical training and custom designed implants for surgical procedures

• Image management Reseller of Mach7’s image management solutions to solutions hospitals and radiology clinics

• Holograms

Sale of EchoPixel Inc’s holographic technology as a diagnostic aid and for preoperative planning

• In theatre image

• 1. manipulation

Sale of GestSure Inc.’s image viewing technology for maintaining a sterile environment in surgery

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

3D PRINTED ANATOMICAL MODELS
Brand name ‘Touch’
----- End of picture text -----

ADVANCING MEDICINE WITH ADDITIVE MANUFACTURING

• Converts anatomical data obtained via CT or MRI scan into physical 3D models

• Works by systematically building up single layers of material to create tactile anatomical models that exactly replicate the data obtained by CT or MRI

• Colour printing highlights anatomical structures & pathologies

• Models can be cut, drilled, or used as visual aids in diagnosis, surgical planning or patient communication

• Can improve efficiency & accuracy in surgery – delivering better patient outcomes

• Supply chain secured via purchase and supply agreement for exclusivity in the medical sector to procure models from largest medical imaging provider in Australia

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

3D PRINTED IMPLANTS
(polymers through to metals)
----- End of picture text -----

ADVANCING MEDICINE WITH ADDITIVE MANUFACTURING

• Anatomical data obtained from conventional scans and capture joint detail and anatomical landmarks

• Medical implants can be created in virtual reality CAD environment by biomedical engineers

• Implant is completely customised to each clinical case using the best design and material composition to suit the unique pathology of the patient

• Implant can be printed in a few hours in a sterile environment and shipped to the hospital

• Disrupts the existing multi-billion dollar ‘standard size’ implant market and radically reduces surgery time in complex or unique cases

• Existing relationships with key hospitals, University's and surgical teams

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

3D PRINTED SURGICAL
CONSUMABLES
----- End of picture text -----

ADVANCING MEDICINE WITH ADDITIVE MANUFACTURING

• Customised healthcare through the design of surgical consumables

• Existing medial image scans are used to personalise single-use items in surgical and clinical treatment contexts

• Highly specialised patient-specific tools can be designed and manufactured for use in surgery

• Electron bean radiation shields can be to target radiotherapy treatments and protect unaffected areas

• Bespoke surgical consumables lower the inventory cost for hospital, decrease the time for surgical and clinical treatments and improve patient outcomes

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

IMAGE MANAGEMENT SOLUTIONS
MACH7
----- End of picture text -----

• 3DM have secured Australasian rights to distribute and resell Mach7’s image management solutions

• Providing healthcare businesses with whole of enterprise image management systems and services that allow them to easily identify, connect and share diagnostic images and patient care intelligence where and when it is needed

• Mach7’s Vendor Neutral Archive allows consolidation of image storage irrespective of the disparate legacy systems the healthcare business is running

• It simplifies access, increases data integrity and heightens security over images and data

• Reseller Agreement with Telstra Health will generate tollbased fee for data packages that travel across Telstra’s cloud-based system

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

HOLOGRAPHIC PROJECTION
Brand name ‘Visualize’
----- End of picture text -----

POWERFUL IMAGING TECHNOLOGY WITH THE POTENTIAL TO SIGNIFICANTLY ALTER THE PRACTICE OF MEDICINE

• Highly sophisticated viewing technology that converts a CT or MRI image into a 3D hologram of the anatomical part, suspended in open air

• Key partnership in place with Silicon Valley based Echopixel Inc.

• Clinicians can interact with the hologram as if it were a real physical object. Possible to manipulate, crop, dissect or segment using a hand-directed stylus

• Improve practitioner efficacy & workflow, provide greater insight into patient anatomy & pathology, & accelerate the pathway to excellence in medical education and training

• FDA approved diagnostic tool

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

IN THEATRE IMAGE MANIPULATION
Product name ‘GestSure’
----- End of picture text -----

ACCESSING DIGITAL PATIENT DATA IN THEATRE USING SIMPLE HAND GESTURES

• Sensor technology developed allows surgeons to manipulate diagnostic images through hand gestures increasing efficiencies and eliminating the need to scrub in and out of surgery

• Exclusive distribution and marketing rights for Australia & New Zealand

• Fast and sterile way to access patient information in the operating theatre that reduces risk of surgical site infection

• Potential to reduce operating times, costs & improve workflow

• Seamless integration into computer. No software or driver installation required

• Requires minimal IT support and compatible with all medical viewers

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

DIRECTORS AND MANAGEMENT
----- End of picture text -----

• Dr Nigel Finch Chairman MCom, LL.M, MBA, Ph.D, CA, CTA, FCPA, F Fin, FTIA, FAICD

Principal at Saki Partners Transaction Advisers. Non Executive Director ASX: SKB Formerly CFO, investment manager, executive director and Associate Dean at the University of Sydney. Management and advisory experience with start up and early stage growth firms.

• Frank Pertile Non Executive Director Grad Dip App Fin, F.FIN

Director of a privately held investment company that holds investments across property, listed and unlisted companies. He is Managing Director 333D, an emerging 3D printing business.

• Stephen Hewitt-Dutton Non Executive Director CA, B.Bus., SA Fin

Associate Director Trident Capital. Non Executive Director ASX: RCM and ASX: FXR 20 years corporate refinance experience and an experienced public company director.

• Max Ghobrial Chief Executive Officer

BSc (Genetics and Biochemistry)

Eight years at Siemens where he held account responsibility for some of Australia’s leading healthcare institutions. He previously held senior roles at Tyco Healthcare and Singtel Optus.

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

FOCUS ON DATA
----- End of picture text -----

PATIENT DATA

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

FOCUS ON DATA
----- End of picture text -----

PATIENT DATA

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

FOCUS ON DATA
----- End of picture text -----

==> picture [243 x 189] intentionally omitted <==

----- Start of picture text -----

PATIENT
DATA
----- End of picture text -----

ANATOMICAL MODELS patient communication, surgical planning

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

FOCUS ON DATA
----- End of picture text -----

==> picture [243 x 189] intentionally omitted <==

----- Start of picture text -----

PATIENT
DATA
----- End of picture text -----

ANATOMICAL MODELS patient communication, surgical planning

ONCOLOGY patient-specific consumables

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

FOCUS ON DATA
----- End of picture text -----

ANATOMICAL MODELS patient communication, surgical planning

PATIENT DATA

ONCOLOGY patient-specific consumables

SURGICAL IMPLANTS customised healthcare, advanced materials and medical-grade titanium

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

FOCUS ON DATA
----- End of picture text -----

MACH7 Vendor Neutral Archive (VNA)

==> picture [321 x 189] intentionally omitted <==

----- Start of picture text -----

PATIENT
DATA
----- End of picture text -----

ANATOMICAL MODELS

patient communication, surgical planning

ONCOLOGY patient-specific consumables

SURGICAL IMPLANTS customised healthcare, advanced materials and medical-grade titanium

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

FOCUS ON DATA
----- End of picture text -----

MACH7 Vendor Neutral Archive (VNA)

ANATOMICAL MODELS

patient communication, surgical planning

ONCOLOGY patient-specific consumables

SURGICAL IMPLANTS customised healthcare, advanced materials and medical-grade titanium

PATIENT DATA ECHOPIXEL clinical efficacy and workflow

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

FOCUS ON DATA
----- End of picture text -----

==> picture [499 x 362] intentionally omitted <==

----- Start of picture text -----

MACH7
Vendor Neutral
Archive (VNA)
PATIENT
DATA
GESTURE
theatre image
management
ECHOPIXEL
clinical efficacy
and workflow
----- End of picture text -----

ANATOMICAL MODELS

patient communication, surgical planning ONCOLOGY patient-specific consumables

SURGICAL IMPLANTS customised healthcare, advanced materials and medical-grade titanium

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

RECENT ANNOUNCEMENTS
----- End of picture text -----

ASX ANNOUNCEMENT 3DM BUSINESS IMPACT

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

RECENT ANNOUNCEMENTS
----- End of picture text -----

ASX ANNOUNCEMENT 3DM BUSINESS IMPACT Leading radiology group in Australia. Foundation customer Exclusive supply agreement to delivering more than one million medical image scans per Capital Health (ASX: CAJ) annum

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

RECENT ANNOUNCEMENTS
----- End of picture text -----

ASX ANNOUNCEMENT Exclusive supply agreement to Capital Health (ASX: CAJ) EchoPixel FDA clearance

3DM BUSINESS IMPACT

Leading radiology group in Australia. Foundation customer delivering more than one million medical image scans per annum Sets a regulatory precedent for EchoPixel as a diagnostic tool paving the way for Australian clinician sales

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

RECENT ANNOUNCEMENTS
----- End of picture text -----

ASX ANNOUNCEMENT

3DM BUSINESS IMPACT

Exclusive supply agreement to Capital Health (ASX: CAJ) EchoPixel FDA clearance

Leading radiology group in Australia. Foundation customer delivering more than one million medical image scans per annum

Sets a regulatory precedent for EchoPixel as a diagnostic tool paving the way for Australian clinician sales

Validates our model to design and deliver implants and work 3D printed metal jaw implant with the spectrum of healthcare stakeholders (including insurers, hospitals, radiology and surgical teams)

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

RECENT ANNOUNCEMENTS
----- End of picture text -----

ASX ANNOUNCEMENT

3DM BUSINESS IMPACT

Exclusive supply agreement to Capital Health (ASX: CAJ)

Leading radiology group in Australia. Foundation customer delivering more than one million medical image scans per annum

EchoPixel FDA clearance

Sets a regulatory precedent for EchoPixel as a diagnostic tool paving the way for Australian clinician sales

3D printed metal jaw implant

Validates our model to design and deliver implants and work with the spectrum of healthcare stakeholders (including insurers, hospitals, radiology and surgical teams)

Telstra Health Mach 7 agreement

First of a number of collaborations with this pre-eminent partner. Delivered a launch customer with substantial earnings due in 3[RD] QTR CY15

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

RECENT ANNOUNCEMENTS
----- End of picture text -----

ASX ANNOUNCEMENT

3DM BUSINESS IMPACT

Exclusive supply agreement to Capital Health (ASX: CAJ)

Leading radiology group in Australia. Foundation customer delivering more than one million medical image scans per annum

EchoPixel FDA clearance

Sets a regulatory precedent for EchoPixel as a diagnostic tool paving the way for Australian clinician sales

3D printed metal jaw implant

Validates our model to design and deliver implants and work with the spectrum of healthcare stakeholders (including insurers, hospitals, radiology and surgical teams)

Telstra Health Mach 7 agreement Genesis CancerCare research collaboration agreement

First of a number of collaborations with this pre-eminent partner. Delivered a launch customer with substantial earnings due in 3[RD] QTR CY15 Largest oncology group in Australia delivering 320,000 radiotherapy treatments per annum

==> picture [720 x 131] intentionally omitted <==

----- Start of picture text -----

QUESTIONS
----- End of picture text -----

Dr. Nigel Finch Chairman, 3D Medical Limited +61 421 742 878

nigel.finch@3Dmedical.com.au www.3Dmedical.com.au